Silicogenix
- Biotech or pharma, therapeutic R&D
Note to services companies: Thanks for your interest, but we are not at the right stage, please skip us. Getting inundated! Thanks
We are a preclinical stage Bay Area Pharma startup applying classical and quantum models to long-standing problems in Discovery Chemistry, with the goal of moving target-molecule sets from "concept to preclinical"in as few as 2 months. We uniquely focus on designing difficult to develop, "fit-for-purpose"molecules (such as allosterically directed, linked and bi-specifics) in <48hrs using our proprietary, ultra-fast frameworks. Our developing patent family impacts areas like Polypharmacology, FBDD, hybrid molecules and allosteric targeting.
We are interested in partnering with companies to conduct feasibility studies for individual targets and target groups, particularly for rare cancers, starting with CLL (anti-CDK9).
Partnership announcement (June 10, 2025): Silicogenix to partner with Bioduro
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}